Interestingly, ectopic expression of the Anks1a PTB domain has a much larger effect on Erk activity and tumour growth than Anks1a-specifc shRNA expression, suggesting that the Anks1a PTB domain is a strong dominant-negative inhibitor of Anks1a in CT26 cells. Here, EPHB2 is linked to neoplasm.